Diagnostic Accuracy and Clinical Utility of InaTB-Rif, Locally Developed Molecular Test for Tuberculosis, in Comparison with Xpert MTB/RIF in Indonesia
DOI:
https://doi.org/10.36497/jri.v45i2.907Keywords:
Ina-TB/RIF, molecular diagnostic test, rifampicin resistance, tuberculosis diagnosis, Xpert MTB/RIFAbstract
Background: Tuberculosis (TB) remains a significant public health issue in Indonesia. Early and accurate diagnosis and drug susceptibility testing are essential for TB management. This study compared the diagnostic accuracy of the locally developed InaTB-Rif molecular test and Xpert MTB/RIF, using Mycobacterium Growth Indicator Tube (MGIT) culture as the reference standard.
Methods: A cross-sectional study was conducted at Persahabatan Hospital, Jakarta, from February to August 2023. Presumptive pulmonary TB patients were recruited and tested using Xpert MTB/RIF, InaTB-Rif, and MGIT culture. The study assessed the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and agreement between InaTB-Rif and Xpert MTB/RIF for Mycobacterium tuberculosis (MTB) detection and rifampicin resistance. Diagnostic accuracy was compared using receiver operating characteristic (ROC) curves.
Results: MGIT culture identified 29 TB-positive and 26 TB-negative cases. InaTB-RIF showed a sensitivity of 93.1% (95% CI=0.77-0.99), specificity of 76.9% (95% CI=0.56-0.91), PPV of 81.8% (95% CI=0.64-0.93), and NPV of 90.9% (95% CI=0.70-0.98). Xpert MTB/RIF had a sensitivity of 89.7% (95% CI=0.726-0.978), specificity of 80.8% (95% CI=0.606-0.93), PPV of 83.9% (95% CI=0.66-0.94), and NPV of 87.5% (95% CI=0.67-0.97). The area under the curve (AUC) was 0.8501 for InaTB-RIF and 0.8521 for Xpert MTB/RIF, with no significant difference in accuracy (P=0.965). The kappa value for MTB detection was 0.776, indicating substantial agreement, while the kappa value for rifampicin resistance detection was 0.517, indicating moderate agreement.
Conclusions: InaTB-RIF demonstrates comparable diagnostic accuracy to Xpert MTB/RIF with good diagnostic performance and agreement for detecting MTB and moderate agreement for rifampicin resistance detection.
Downloads
References
1. World Health Organization. Global tuberculosis report 2023 [Internet]. [cited 2024 Aug 13]. Available from: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2023
2. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new end TB strategy. Lancet. 2015;385:1799–801.
3. World Health Organization. Global tuberculosis report 2024 [Internet]. [cited 2024 Aug 13]. Available from: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2024
4. World Health Organization. WHO standard : Universal access to rapid tuberculosis diagnostics. Geneva; 2023.
5. Wu Z, Rueda ZV, Li T, Zhang Z, Jiang Y, Sha W, et al. Effect of the Xpert MTB/RIF on the detection of pulmonary tuberculosis cases and rifampicin resistance in Shanghai, China. BMC Infect Dis. 2020;20.
6. Ershova J V., Volchenkov G V., Somova TR, Kuznetsova TA, Kaunetis N V., Kaminski D, et al. Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia. BMC Infect Dis. 2020;20:543.
7. Acharya B, Acharya A, Gautam S, Ghimire SP, Mishra G, Parajuli N, et al. Advances in diagnosis of tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosis. Mol Biol Rep. 2020;47:4065–75.
8. Pinto LM, Udwadia ZF. Xpert MTB/RIF and pulmonary tuberculosis: time to delve deeper? Thorax. 2013;68:987.
9. Cazabon D, Pande T, Kik S, Van Gemert W, Sohn H, Denkinger C, et al. Market penetration of Xpert MTB/RIF in high tuberculosis burden countries: a trend analysis from 2014-2016. Gates Open Res. 2018;2:35.
10. Agredo F, Osorio L. Coverage and fidelity of the Xpert MTB/RIFTM implementation in a high-burden area for pulmonary tuberculosis in Colombia. Biomedica. 2020;40:626–40.
11. Nalugwa T, Shete PB, Nantale M, Farr K, Ojok C, Ochom E, et al. Challenges with scale-up of GeneXpert MTB/RIF® in Uganda: a health systems perspective. BMC Health Serv Res. 2020;20:162.
12. Directorate General of Prevention and Disease Control. Tuberculosis control in Indonesia 2022. Indonesia; 2022.
13. Phyu MH, Kyaw KWY, Myint Z, Thida A, Satyanarayana S, Aung ST. Sputum smear-positive, Xpert ® MTB/RIF-negative results: magnitude and treatment outcomes of patients in Myanmar. Public Health Action. 2019;8:181–6.
14. Zetola NM, Shin SS, Tumedi KA, Moeti K, Ncube R, Nicol M, et al. Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by genexpert MTB/RIF are associated with poor clinical outcomes. J Clin Microbiol. 2014;52:2422–9.
15. Ngangue YR, Mbuli C, Neh A, Nshom E, Koudjou A, Palmer D, et al. Diagnostic accuracy of the truenat MTB plus assay and comparison with the Xpert MTB/RIF assay to detect tuberculosis among hospital outpatients in Cameroon. J Clin Microbiol. 2022;60:e0015522.
16. Burhan E, Karyana M, Karuniawati A, Kusmiati T, Wibisono BH, Handayani D, et al. Characteristics of drug-sensitive and drug-resistant tuberculosis cases among adults at tuberculosis referral hospitals in Indonesia. Am J Trop Med Hyg. 2022;107:984–91.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Diah Handayani, Budi Haryanto, Galoeh Adyasiwi, Muhammad Sopiyudin Dahlan, Heidi Agustin, Muhammad Prasetio Wardoyo, Ahmad Fadhil Ilham, Erlina Burhan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
